Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · IEX Real-Time Price · USD
10.05
+0.67 (7.14%)
May 17, 2024, 4:30 PM EDT - Market closed
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.
Its lead product candidate is ELI-002, a multivalent lymph node"targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company is also developing ELI-007, a multivalent lymph node"targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine to target p53 hotspot mutations.
The company is headquartered in Boston, Massachusetts.
Elicio Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Robert T. Connelly |
Contact Details
Address: One Kendall Square, Building 1400 West, Suite 14303 Cambridge, Massachusetts 02139 United States | |
| Phone | 857-209-0056 |
| Website | elicio.com |
Stock Details
| Ticker Symbol | ELTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555192 |
| CUSIP Number | 28657F103 |
| ISIN Number | US28657F1030 |
| Employer ID | 45-2966790 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert T. Connelly | Chief Executive Officer, President and Director |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Prof. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board |
| Brian Piekos | Chief Financial Officer |
| Michael DiVecchia | Senior Vice President of Operations and Human Resources |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Megan C. Filoon | General Counsel, Secretary and Compliance Officer |
| Esther Welkowsky | Senior Vice President of Clinical Development |
| Joy Seymour | Vice President and Head of Regulatory Affairs |
| Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 2, 2022 | D/A | Filing |
| Sep 13, 2022 | RW | Filing |
| May 27, 2022 | D | Notice of Exempt Offering of Securities |
| Nov 18, 2021 | D/A | Filing |
| Nov 12, 2021 | D/A | Filing |
| Oct 19, 2021 | D | Notice of Exempt Offering of Securities |
| Jul 13, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 29, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 9, 2021 | DRS/A | [Amend] [Cover] Draft Registration Statement |